170 related articles for article (PubMed ID: 38089508)
1. Corneal epithelial changes in a patient treated with belantamab mafodotin.
Inferrera L; Giglio R; Tognetto D
Taiwan J Ophthalmol; 2023; 13(3):380-383. PubMed ID: 38089508
[TBL] [Abstract][Full Text] [Related]
2. Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.
Matsumiya W; Karaca I; Ghoraba H; Akhavanrezayat A; Mobasserian A; Hassan M; Regenold J; Yasar C; Liedtke M; Kitazawa K; Nguyen QD
Am J Ophthalmol Case Rep; 2021 Sep; 23():101133. PubMed ID: 34169181
[TBL] [Abstract][Full Text] [Related]
3. A novel agent for myeloma causing toxic keratopathy, belantamab mafodotin: a case report and literature review.
Kurt RA; Gören D; Karadeniz S; Arat M; Sahin A
Arq Bras Oftalmol; 2022 Nov; ():. PubMed ID: 36350901
[TBL] [Abstract][Full Text] [Related]
4. Belantamab mafodotin associated corneal microcyst-like epithelial changes.
Chuang K; Pineda R; Liu S
Am J Ophthalmol Case Rep; 2022 Mar; 25():101392. PubMed ID: 35198816
[TBL] [Abstract][Full Text] [Related]
5. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ; Jeng BH; Callander NS; Opalinska J; Baron J; Piontek T; Byrne J; Gupta I; Colby K
Ophthalmol Ther; 2020 Dec; 9(4):889-911. PubMed ID: 32712806
[TBL] [Abstract][Full Text] [Related]
6. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
[TBL] [Abstract][Full Text] [Related]
7. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report.
Marquant K; Quinquenel A; Arndt C; Denoyer A
J Hematol Oncol; 2021 Oct; 14(1):159. PubMed ID: 34602074
[TBL] [Abstract][Full Text] [Related]
8. Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma.
Gallin V; Nölle B; Schub N; Roider J
Cornea; 2024 Jun; ():. PubMed ID: 38900711
[TBL] [Abstract][Full Text] [Related]
9. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.
Wahab A; Rafae A; Mushtaq K; Masood A; Ehsan H; Khakwani M; Khan A
Front Oncol; 2021; 11():678634. PubMed ID: 34046363
[TBL] [Abstract][Full Text] [Related]
10. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
Becnel MR; Lee HC
Ther Adv Hematol; 2020; 11():2040620720979813. PubMed ID: 33403093
[TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K
Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771
[TBL] [Abstract][Full Text] [Related]
13. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
[TBL] [Abstract][Full Text] [Related]
14. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Offidani M; Corvatta L; Morè S; Olivieri A
Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
[TBL] [Abstract][Full Text] [Related]
15. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
Lonial S; Nooka AK; Thulasi P; Badros AZ; Jeng BH; Callander NS; Potter HA; Sborov D; Zaugg BE; Popat R; Degli Esposti S; Byrne J; Opalinska J; Baron J; Piontek T; Gupta I; Dana R; Farooq AV; Colby K; Jakubowiak A
Blood Cancer J; 2021 May; 11(5):103. PubMed ID: 34039952
[TBL] [Abstract][Full Text] [Related]
16. Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy.
Fazio F; Petrucci MT; Corvatta L; Piciocchi A; Pepa RD; Tacchetti P; Musso M; Zambello R; Belotti A; Bringhen S; Antonioli E; Conticello C; Renzo ND; De Stefano V; Musto P; Gamberi B; Derudas D; Boccadoro M; Offidani M; Morè S
EJHaem; 2024 Jun; 5(3):485-493. PubMed ID: 38895069
[TBL] [Abstract][Full Text] [Related]
17. Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City.
Jaber W; Abdaljalil A; Ali A; Abu Haleeqa M; Mheidly K
Cureus; 2023 Aug; 15(8):e44433. PubMed ID: 37791224
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.
Cardellino A; Correll JR; Martin M; Gorsh B; Sapra S; Popat R
Front Oncol; 2023; 13():1274659. PubMed ID: 38144529
[TBL] [Abstract][Full Text] [Related]
19. Belantamab mafodotin for the treatment of multiple myeloma.
Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
Baines AC; Ershler R; Kanapuru B; Xu Q; Shen G; Li L; Ma L; Okusanya OO; Simpson NE; Nguyen W; Theoret MR; Pazdur R; Gormley NJ
Clin Cancer Res; 2022 Nov; 28(21):4629-4633. PubMed ID: 35736811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]